ECSP11010744A - PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA - Google Patents

PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA

Info

Publication number
ECSP11010744A
ECSP11010744A EC2011010744A ECSP11010744A ECSP11010744A EC SP11010744 A ECSP11010744 A EC SP11010744A EC 2011010744 A EC2011010744 A EC 2011010744A EC SP11010744 A ECSP11010744 A EC SP11010744A EC SP11010744 A ECSP11010744 A EC SP11010744A
Authority
EC
Ecuador
Prior art keywords
benzoimidazol
preparation
pyrimidine derivatives
methyl
hemitartrate
Prior art date
Application number
EC2011010744A
Other languages
English (en)
Inventor
Sergio Cesco-Cancian
Neelakandha Mani
David C Palmer
Tong Xiao
Christopher Mapes
Daniel J Pippel
Jeffrey S Grimm
Diego Broggini
Susanne Lochner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010744(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP11010744A publication Critical patent/ECSP11010744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a los procesos para la preparación de derivados de benzoimidazol-2-il pirimidina útiles como moduladores del receptor H4 de histamina, y un hemitartrato cristalino de [5-(4,6-dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina.
EC2011010744A 2008-06-30 2011-01-05 PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA ECSP11010744A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7675908P 2008-06-30 2008-06-30

Publications (1)

Publication Number Publication Date
ECSP11010744A true ECSP11010744A (es) 2011-02-28

Family

ID=41426846

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010744A ECSP11010744A (es) 2008-06-30 2011-01-05 PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA

Country Status (27)

Country Link
US (3) US20100029942A1 (es)
EP (2) EP2303869A2 (es)
JP (2) JP2011526911A (es)
KR (1) KR20110022721A (es)
CN (2) CN103319459A (es)
AR (1) AR072397A1 (es)
AU (1) AU2009267159B2 (es)
BR (1) BRPI0913989A2 (es)
CA (1) CA2729703A1 (es)
CL (1) CL2010001639A1 (es)
CO (1) CO6341626A2 (es)
CR (1) CR20110057A (es)
EA (1) EA020090B1 (es)
EC (1) ECSP11010744A (es)
IL (1) IL210213A (es)
MX (1) MX2011000081A (es)
MY (1) MY157197A (es)
NI (1) NI201000233A (es)
NZ (2) NZ599747A (es)
PE (1) PE20140592A1 (es)
SG (1) SG192446A1 (es)
SV (1) SV2011003789A (es)
TW (2) TW201018668A (es)
UA (1) UA102855C2 (es)
UY (1) UY31951A (es)
WO (1) WO2010002777A2 (es)
ZA (1) ZA201100760B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51423B (en) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
MX2011000080A (es) * 2008-06-30 2011-03-02 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de pirimidina sustituidos.
AU2009267159B2 (en) 2008-06-30 2014-05-15 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
ES2773543T3 (es) * 2013-03-06 2020-07-13 Janssen Pharmaceutica Nv Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
EA200000840A1 (ru) * 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
DE60122944T2 (de) * 2000-04-24 2007-04-12 Teva Pharmaceutical Industries Ltd. Mikronisiertes Zolpidem-Hemitartrat
US6693194B2 (en) 2000-07-21 2004-02-17 Syngenta Crop Protection, Inc. Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
NZ546259A (en) * 2003-09-30 2009-05-31 Janssen Pharmaceutica Nv Benzoimidazole compounds
AU2004316266A1 (en) * 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
WO2005092066A2 (en) 2004-03-25 2005-10-06 Janssen Pharmaceutica N.V. Imidazole compounds
SG157378A1 (en) * 2004-09-27 2009-12-29 Acadia Pharm Inc Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
RS51423B (en) * 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
JP2009532367A (ja) * 2006-03-31 2009-09-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリジン
AU2009267159B2 (en) 2008-06-30 2014-05-15 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives

Also Published As

Publication number Publication date
MX2011000081A (es) 2011-03-02
NZ599747A (en) 2013-03-28
TW201018668A (en) 2010-05-16
US8921550B2 (en) 2014-12-30
US20100029942A1 (en) 2010-02-04
JP2011526911A (ja) 2011-10-20
WO2010002777A3 (en) 2010-06-24
WO2010002777A2 (en) 2010-01-07
EA201170114A1 (ru) 2011-08-30
JP2014040426A (ja) 2014-03-06
CR20110057A (es) 2013-01-25
ZA201100760B (en) 2012-07-25
KR20110022721A (ko) 2011-03-07
BRPI0913989A2 (pt) 2015-10-20
EP2303869A2 (en) 2011-04-06
IL210213A (en) 2015-08-31
EP2865678A3 (en) 2015-05-27
NZ590169A (en) 2012-05-25
US20120184740A1 (en) 2012-07-19
SG192446A1 (en) 2013-08-30
CO6341626A2 (es) 2011-11-21
US20120178932A1 (en) 2012-07-12
CN103319459A (zh) 2013-09-25
UY31951A (es) 2010-01-29
TWI485147B (zh) 2015-05-21
EA020090B1 (ru) 2014-08-29
PE20140592A1 (es) 2014-05-16
MY157197A (en) 2016-05-13
UA102855C2 (ru) 2013-08-27
TW201422609A (zh) 2014-06-16
IL210213A0 (en) 2011-03-31
SV2011003789A (es) 2011-04-08
CL2010001639A1 (es) 2011-06-24
US8835633B2 (en) 2014-09-16
CN102137857A (zh) 2011-07-27
AU2009267159A1 (en) 2010-01-07
AU2009267159B2 (en) 2014-05-15
CA2729703A1 (en) 2010-01-07
AR072397A1 (es) 2010-08-25
EP2865678A2 (en) 2015-04-29
NI201000233A (es) 2011-11-09

Similar Documents

Publication Publication Date Title
ECSP11010744A (es) PROCESO PARA LA PREPARACIÓN DE DERIVADOS DE BENZOIMIDAZOL-2-Il PIRIMIDINA
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
CR20140222A (es) Nuevos derivados de [1,2,3] triazolo [4,5-d] pirimidina como agonistas del receptor 2 de agonistas canabinoides
AU2012334173A8 (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
CU23911B1 (es) Derivados de amida espiro - ciclícas como moduladores de beta-2-adrenoreceptores útiles para el tratamiento de la bronquitis y el asma
CU20150123A7 (es) DOS FORMAS CRISTALINAS DEL COMPUESTO( 4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO?(3,4-b)PIRIDIN-3-IL)PIRIMIDIN-5-IL)CARBAMATO DE METILO
SV2011003831A (es) Compuestos organicos
EA024893B9 (ru) БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ
PE20151536A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
CY1114427T1 (el) Παραγωγα 4-αμινοπυριμιδινης ως ανταγωνιστες υποδοχεα ισταμινης η4
ECSP11010745A (es) Proceso para la preparación de derivados de pirimidina sustituidos
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
ECSP12011923A (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
PE20180316A1 (es) Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
ME00929B (me) NOVI POSTUPAK ZA DOBlJANJE KRISTALNOG OBLIKA V AGOMELATIN A
MX345142B (es) Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
UA105320C2 (ru) Соединения дигидробензоксатиазепина, способ их получения и фармацевтическая композиция, которая их содержит
CL2010001635A1 (es) Derivados de pirimidinas utiles como moduladores del receptor h4; y su procedimiento de preparacion.
UY32506A (es) Sintesis quimica mejorada para producir diazaindoles
GT200800195A (es) Procedimiento para la preparación de derivados de ciclopropilamida
AU2011355362A8 (en) 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives
TH131037B (th) การใช้ของอนุพันธ์ของไพริมิดิลอะมิโนเบนซาไมด์ สำหรับการบำบัดรักษาของ การสร้างหรือเกิดเนื้อเส้นใยอย่างผิดปกติ